Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

Jo Anne H. van Burik, Roberta S. Hare, Howard F. Solomon, Michael L. Corrado, Dimitrios P. Kontoyiannis

Research output: Contribution to journalArticlepeer-review

548 Scopus citations

Abstract

To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we conducted a retrospective study including 91 patients with zygomycosis (proven zygomycosis, 69 patients; probable zygomycosis, 22 patients). Patients had infection that was refractory to prior antifungal treatment (n=81) or were intolerant of such treatment (n=10) and participated in the compassionate-use posaconazole (800 mg/day) program. The rate of success (i.e., either complete or partial response) at 12 weeks after treatment initiation was 60%, and 21% of patients had stable disease. The overall high success and survival rates reported here provide encouraging data regarding posaconazole as an alternative therapy for zygomycosis.

Original languageEnglish (US)
Pages (from-to)e61-65
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume42
Issue number7
DOIs
StatePublished - Apr 1 2006

Fingerprint

Dive into the research topics of 'Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.'. Together they form a unique fingerprint.

Cite this